Work report of the board of directors in 2021
In 2021, all members of the board of directors of Guangdong Transtek Medical Electronics Co.Ltd(300562) (hereinafter referred to as “the company”) earnestly performed the duties of the board of directors entrusted by the general meeting of shareholders in accordance with the requirements of the company law, the securities law and other laws and regulations and the articles of Association, starting from the practical protection of the interests of the company, the rights and interests of shareholders and all employees, combined with the actual situation of the company, and with the attitude of conscientious and diligent work, Strictly implement the resolutions of the general meeting of shareholders, carry out all work diligently and conscientiously, actively promote the implementation of the resolutions of the board of directors, continuously strengthen internal control, improve the corporate governance structure, further improve the standardized operation ability of the company, ensure the scientific decision-making of the board of directors, actively promote the development of all businesses of the company around the company’s development strategy and work policy, and now report the work of the board of directors of the company in 2021 as follows: Review of operation in 2021
2021 is the first year of the 14th five year plan and a key year for Guangdong Transtek Medical Electronics Co.Ltd(300562) strategic innovation. Seizing the rapid development opportunities of health IOT and digital health industry, the company actively conforms to the national strategic development direction of healthy China and digital transformation. With years of experience in intelligent health hardware, big data, Internet of things, Internet and deep health industry, the company is committed to becoming a world-class health IOT and digital health service provider.
Relying on its unique advantages in product innovation and R & D, product quality and application technology in the fields of intelligent medical health and intelligent wearable, the company deeply integrates health IOT, big data and medical treatment to form a two wheel driven main business layout of “health IOT + digital health service”. According to the existing business attributes and strategic deployment, the company focuses on the vertical field of health management, actively seizes the “digital” strategic outlet, first publishes the Bureau’s digital health business, provides industry customers with digital health management overall solutions with Internet of things and Internet capabilities, actively promotes the transformation of digital enabled health management industry, and further improves the ecological closed loop in the field of Guangdong Transtek Medical Electronics Co.Ltd(300562) remote health management, Welcome the digital economic era of remote health management.
1. Improve the layout of health IOT industry, focus on remote health management business, and continuously improve the industry competitiveness
With the breakthrough of basic technologies such as Internet of things, big data, AI and cloud computing and the rapid popularization of 5g mobile communication technology, it can effectively drive the digital, networked and intelligent upgrading of medical and health management. Medical level remote health management based on aiot and mobile network technology will greatly change the form of medical, health and health management in the future society, The market puts forward more application requirements for the development and service of remote science and technology products related to medical level health management.
In 2021, the company focused on remote health management business, gave full play to the company’s core advantages, combined health IOT products with medical services, and provided customers with overall solutions for remote health management. The company actively explores the application of emerging technologies in the remote health management business, uses emerging technologies to inject new energy into the overall solution of the company’s remote health management, and speeds up the business development and expansion of remote health management to achieve profitability. Remote health management business (RPM) is in line with the medical and health service category committed to the development of the country, and will further enhance the comprehensive competitiveness of Lexin.
2. Based on innovation drive, attach great importance to the improvement of R & D ability and build differentiated competitiveness
The company has always been driven by R & D and innovation. In 2021, the company will continue to increase investment in wearable biosensor technology (ECG, body temperature monitoring, blood oxygen, blood pressure detection, PPG, etc.), continuously strengthen the improvement of core components and algorithm capabilities, the development of health big data and the R & D layout of user operation capabilities, and promote the product application of chronic disease management in blood pressure, cardiovascular and other aspects. With the company’s development strategy as the core, while continuously strengthening independent innovation, we will accelerate the listing of new products in line with the company’s strategic direction, enrich the company’s product line and enhance product competitiveness through cooperation with foreign technical teams and R & D institutions with mature technology.
During the reporting period, the total R & D investment of the company was 1618203 million yuan, accounting for 8.89% of the operating revenue, with a year-on-year increase of 41.55%. There were more than 400 R & D personnel, accounting for 19.77% of the total number of employees. The company has talents in structure, firmware, electronics, computer software, algorithms, management and other aspects. The company has always focused on improving the intellectual property protection system, actively invested in intellectual property management, has a full-time intellectual property team with professional qualifications and professional ability, has a mature class II medical equipment production system and medical certification in mainstream countries around the world.
By the end of the reporting period, the company had obtained 533 patent certificates, including 86 invention patents, 215 utility model patents and 232 design patents. It has obtained 45 software copyrights, 512 Chinese registered trademarks, 25 overseas patent certificates and 100 overseas registered trademarks.
During the reporting period, the company added 102 patent applications in China, including 31 invention patents, 55 utility model patents and 16 design patents. 114 newly authorized patents were added, including 25 invention patents, 49 utility model patents and 40 design patents; 16 new applications for Chinese trademarks, 27 new Chinese registered trademarks, 12 new overseas trademark applications and 2 new overseas registered trademarks were added.
3. Build comprehensive talent competitiveness, build a modern human resource management system, and carry out organizational and talent reform
It is a strong support for the company’s customer-oriented and orderly organization at all levels. It is a strong support for the construction of the front desk and the back desk. It is a strong support for the customer-oriented and orderly organization at all levels of the company, and runs through the front desk and the back desk. In terms of cadre management, we should strengthen the ability of cadres and enrich the cadre echelon. Through a series of leadership training, we should identify and cultivate excellent and potential cadres, and introduce a large number of external excellent cadres with high educational level, senior industry experience and rich management practice, so as to continuously improve the combat effectiveness of cadres. In terms of talent team construction, the comprehensive use of talent inventory, organizational diagnosis, performance evaluation, salary incentive and other means to gain insight into the current situation of talent echelon, take strengthening the foundation as the primary goal, quickly fill vacancies, focus on retaining talents, strengthen internal training, deepen inheritance, stimulate vitality and efficient output, and improve the cohesion and combat effectiveness of talent team.
4. Comprehensively promote cost reduction and efficiency increase, lean management and continuously improve operation efficiency
During the reporting period, the company actively promoted lean management. By strengthening the cost analysis of all links of the supply chain, optimizing product technology and other measures, the company carried out cost reduction and efficiency increase in all aspects, and the overall production and operation of the company maintained a good operation trend. According to the project needs of existing international head enterprise customers and newly introduced strategic customers, continuously optimize the supply chain service system, cooperate with the promotion of high delivery quality of various projects, and better serve the company’s market and customer strategy. With the gradual improvement of the influence of the industry, it has more initiative in the selection of core materials and key components, can get stronger support on the supply side, and the overall supply chain system has been further optimized.
5. Implement private placement, enhance capital strength, and boost the strategic layout of health IOT and digital health services
The company adheres to the strategy of joint promotion and mutual support of endogenous growth and epitaxial development, fully combines the development situation of the industry, actively allocates resources, continuously optimizes the capital structure, improves the capital strength, and provides support for the sustainable development of the company. During the reporting period, the company accelerated the construction of IPO raised investment projects. The main body of phase III project of Lexin Industrial Park invested and constructed with raised funds has completed the acceptance, and the production workshop has started the production line decoration construction at the same time. The total construction area of the project is about 40000 square meters, mainly building intelligent production plants, automatic production lines, fully automatic three-dimensional warehouses, fully automatic logistics transmission lines, R & D laboratories, advanced experimental and testing equipment, etc. The accelerated implementation of raised investment projects is conducive to the company’s overall planning and rational layout, enhance the company’s scale advantages and the integration advantages of the whole industrial chain, and meet the company’s long-term development needs.
During the reporting period, the company implemented the issue of A-Shares to specific objects, and completed the issuance and listing of this private placement on March 11, 2022. The total amount of funds raised in this issuance is 395 million yuan. The implementation of this project will help Guangdong Transtek Medical Electronics Co.Ltd(300562) enrich the product line in the field of health IOT and remote health management. At the same time, through the R & D project, improve the data index accuracy of the company’s sphygmomanometers, blood glucose meters, ECG monitoring products, intelligent scales and other products, improve and upgrade the remote health management system, and make the company’s products have higher added value Move forward in the field of higher competitiveness, improve the profitability and market competitiveness of the company, meet the needs of the rapid development of health IOT and remote health management industry, and open up new business areas and space for the sustainable development of the company in health IOT and remote health management industry.
6. Improve the corporate governance structure, comply with regulations and ensure sustainable development
The company has always attached great importance to the standardized management within the group, and continuously improved and improved the internal control system and corporate governance structure in strict accordance with the company law, securities law, Shenzhen Stock Exchange GEM Listing Rules, Shenzhen Stock Exchange self regulatory guidelines for listed companies No. 2 – standardized operation of listed companies on gem and other laws and regulations, normative documents and relevant regulations and requirements of regulatory authorities, Further strengthen the standardized operation mechanism of the “three meetings”, strengthen the sense of responsibility and law-abiding awareness of directors, supervisors, senior managers and core teams, sort out the company’s organizational structure, actively promote the construction of internal control, information disclosure and investor relations, improve the level of corporate governance and ensure the healthy, stable and sustainable development of the company.
During the reporting period, the company further strengthened the management of investor relations. In addition to communicating with investors through investor hotline, IR email, interactive platform of Shenzhen Stock Exchange and performance presentation meeting, the company also held several Wuxi Online Offline Communication Information Technology Co.Ltd(300959) meetings from time to time to communicate timely and effectively with institutional and individual investors, enhancing investors’ understanding and recognition of the company’s value, Enhance the company’s brand image in the capital market. At the same time, in strict accordance with the provisions of laws, regulations and normative documents, the company carefully followed the authenticity, accuracy, timeliness and integrity of information disclosure, fulfilled the obligation of information disclosure in accordance with the provisions, maintained the company’s open and transparent good market image, and effectively protected the interests of all shareholders.
In terms of internal construction of the company, in combination with the actual production and operation needs and actual situation of the company, strengthen risk prevention and control, gradually improve the operable internal control system within the company, and avoid damaging the interests of listed companies and shareholders due to imperfect internal control; Steadily promoted the comprehensive budget management system, continued to improve the information construction and optimization of management systems such as financial data analysis system, and laid the foundation for the steady development of the company.
2、 Overview of operating performance in 2021
During the reporting period, due to the multiple drivers of the global epidemic, the intensification of population aging, the improvement of residents’ living standards, the improvement of residents’ health awareness and the favorable government medical policies, the demand for medical IOT and digital medical treatment has become increasingly prominent. In 2021, with the mission of “digital health protection”, the company joined hands with global partners to actively participate in the construction of global digital medical and health service network with innovation and services, and achieved good results.
In the face of the complex global economic situation and the downward pressure of the economy, the company closely focuses on the medium and long-term strategic goal of “becoming a world-class health IOT and digital health service provider”, adheres to user-centered, focuses on the core main business, continuously deepens the cooperation with global strategic partners, continues to strengthen the development of new markets and customers, and actively responds to the challenges of market risks and various adverse factors, To ensure the timely delivery of our products and services, the company achieved rapid growth in all product lines and overall sales revenue. During the reporting period, the company achieved an operating revenue of 18210725 million yuan, an increase of 36.23% over the same period last year. During the reporting period, the net profit attributable to the shareholders of the parent company was 8.8688 million yuan, a decrease of 87.36% over the same period of the previous year. The main reasons affecting profits are as follows:
1. During the reporting period, due to the serious shortage of key materials such as global chips and electronic components, the sharp rise in the price of upstream raw materials, the shortage of energy and the sharp decline in global logistics efficiency, the production cost during the reporting period increased significantly compared with the same period of last year, which had a great adverse impact on the profits of the current period.
2. At this stage, the overall scale of the company’s overseas business accounts for a large proportion. The quotation of long-term framework contracts and orders settled in foreign currency is relatively stable and the price adjustment mechanism is insufficient. During the reporting period, the fluctuation of US dollar exchange rate and the appreciation of RMB have a great impact on the profits of the current period.
3. The company focused on the implementation and reform of the new strategy of medical and health IOT and digital medicine. In order to build the company’s long-term driving force, the company continued to increase technology and product innovation and R & D in the fields of telemedicine, household medicine, primary medical treatment, chronic disease management and so on. During the reporting period, the company significantly increased its long-term R & D investment, which was significantly higher than that in the same period of last year.
3、 Work of the board of directors in 2021
1. Meetings of the board of directors
In 2021, the board of directors of the company held 8 meetings. The board of directors of the company made decisions on relevant matters of the company in strict accordance with the requirements of the company law, securities law and other laws and regulations and the articles of association. The convening conditions and resolutions of each meeting are as follows:
Time of convening meeting and matters to be considered at the session
1. The proposal on adjusting the investment amount of investment projects raised by issuing shares to specific objects was deliberated and adopted
2. The proposal on using raised funds to replace self raised funds that have been invested in raised investment projects in advance and paid issuance expenses was deliberated and adopted
The third session of the third board of Directors examined and approved the proposal on changing the registered capital and amending the articles of association on March 29, 2021
4. The 19th meeting deliberated and adopted the proposal on the joint foreign investment and establishment of companies and related party transactions between the company and related parties
5. Deliberated and adopted the draft decision on
